Company intelligence / Profile preview

FuturaGene

São Paulo, São Paulo, Brazilfuturagene.com ↗

Ownership: Private
Employees: ~76
Development stage: Other

Overview

FuturaGene developed the world’s first genetically modified eucalyptus with increased productivity, receiving regulatory approval in Brazil in April 2015. Multi-year field trials demonstrated significant wood yield gains without adverse environmental impact compared to conventional eucalyptus. The technology involves introducing a gene from Arabidopsis thaliana to accelerate growth via enhanced cell wall biosynthesis.[4][1][5]

Modalities: Genetic engineeringGenetically modified plants (GMOs)
Industry: Non-Drug Biotech

Partnerships

Embrapa (Brazilian Agricultural Research Corporation)São Paulo University (USP)São Paulo State University (UNESP)Viçosa Federal University (UFV)China Academy of ForestryOther partnerships under confidentiality agreements with international leaders in silviculture/agriculture.

Beyond the preview

Go deeper on FuturaGene.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FuturaGene.

Explore the full profile